Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01418651 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Milnacipran in the Treatment of Fibromyalgia in an Elderly Population
A Phase 3 study, sponsored by Banner Health.
- Terminated
- Registry status
- Phase 3
- Development phase
- 20
- Enrollment target
NCT01418651 is a Phase 3 study that was terminated before completion, run by Banner Health. The registered enrollment target is 20 participants.
The verdict
NCT01418651, a Phase 3 study, was terminated before completion, sponsored by Banner Health.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 20 participants
- Enrollment target
Study Summary
Participants will undertake a 12-week, open-label study of milnacipran in a well-characterized cohort of patients with fibromyalgia syndrome (FMS) who are 65 years and older to investigate the short-term efficacy and safety of this drug in the elderly population. The investigators hypothesize that milnacipran will be effective in treating fibromyalgia syndrome (FMS), and will be prove to be safe when patients are selected for the absence of pre-existing blood pressure abnormalities and other serious medical conditions.
Interventions
- DRUG Savella
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2011-03 |
| Est. Completion | 2011-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01418651
The ClinicalTrials.gov registry entry for NCT01418651 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Banner Health, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Savella is the first listed.
NCT01418651 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01418651 about?
NCT01418651 is a clinical study titled "Efficacy and Safety of Milnacipran in the Treatment of Fibromyalgia in an Elderly Population". Participants will undertake a 12-week, open-label study of milnacipran in a well-characterized cohort of patients with fibromyalgia syndrome (FMS) who are 65 years and older to investigate the short-term efficacy and safety of this drug in the elderly population. The investigators hypothesize that m...
What is the current status of trial NCT01418651?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 20 participants. The study started on 2011-03. Estimated completion is 2011-08.
What interventions are being tested in trial NCT01418651?
The interventions under investigation include: Savella (DRUG).
Who is sponsoring clinical trial NCT01418651?
This trial is sponsored by Banner Health, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.